Cytoskeletal Remodelling as an Achilles' Heel for Therapy Resistance in Melanoma

Area of Science:

• Oncology
• Dermatology
• Cell Biology

Background:

• Melanoma is an aggressive skin cancer with poor prognosis, particularly when diagnosed late.
• Current therapies like MAPK-targeted treatments and immune checkpoint blockers benefit only a subset of patients.
• Acquired or intrinsic resistance to these therapies is a significant clinical challenge.

Purpose of the Study:

• To review current knowledge on cytoskeletal pathways involved in melanoma therapy resistance.
• To explore future therapeutic avenues targeting cytoskeletal signaling in resistant melanoma.
• To discuss potential clinical interventions for overcoming melanoma drug resistance.

Main Methods:

• Literature review and synthesis of existing research on melanoma therapy resistance.
• Analysis of the role of cytoskeleton regulators and actomyosin remodeling in drug resistance.
• Identification of therapeutic vulnerabilities associated with cytoskeletal dependency.

Main Results:

• Therapy-resistant melanoma cells exhibit significant rewiring of cytoskeleton regulators.
• Actomyosin cytoskeleton remodeling is a key adaptation in resistant melanoma cells.
• Cytoskeletal signaling pathways become critical for survival under drug pressure in resistant cells.

Conclusions:

• Cytoskeletal remodeling is a crucial mechanism underlying melanoma therapy resistance.
• The dependency of resistant cells on cytoskeletal pathways presents a therapeutic vulnerability.
• Targeting cytoskeletal signaling pathways holds promise for novel melanoma treatment strategies.